IL17A and COVID-19: Our previous study of 374 patients with psoriasis and COVID‐19 reported to the PsoProtect registry further suggested an association between biologics (pooled data on TNF, IL‐17 and IL‐23 inhibitors) and reduced risk of hospitalization, compared with standard systemic therapies.18